Lobsor's lightweight PD therapy presents serious threat to AbbVie

Swedish startup Lobsor has won its first approval for Lecigon (levodopa/carbidopa/entacapone), a new therapeutic system for symptomatic treatment of advanced Parkinson’s disease, a decision which could shake up a market dominated by AbbVie (NYSE: ABBV).

Lobsor’s option has the advantage of being more lightweight than AbbVie’s Duodopa (levodopa/carbidopa) product, which is now more than a decade old.

The firm says that “the combination of lower dosage and lighter pump is designed to significantly improve patient convenience and quality of life.”